18F-FDG PET/CT and lung cancer: Value of fourth and subsequent posttherapy follow-up scans for patient management

Journal of Nuclear Medicine

Volumn 56, Issue 2, 2015, Pages 204-208

  Marcus, Charles ^a   Paidpally, Vasavi ^a   Antoniou, Alexander ^a   Zaheer, Atif ^a   Wahl, Richard L ^a   Subramaniam, Rathan M ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Clinical suspicion; Follow up; Lung cancer; PET CT; Recurrence; Treatment change

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BRONCHIOALVEOLAR CARCINOMA; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL EVALUATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; FIBROMA; FOLLOW UP; HEALTH IMPACT ASSESSMENT; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; METASTASIS; NON SMALL CELL LUNG CANCER; PATIENT CARE; POSTOPERATIVE CARE; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; TERTIARY HEALTH CARE; TREATMENT RESPONSE; BIOPSY; COMPUTER ASSISTED TOMOGRAPHY; ECONOMICS; LUNG NEOPLASMS; MEDICARE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM RECURRENCE, LOCAL; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SCINTISCANNING; UNITED STATES;

AGED; BIOPSY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MEDICARE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES;

EID: 84922068075     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.147884     Document Type: Article

References (19)

1. Key Statistics about Lung Cancer. Atlanta, Georgia: American Cancer Society; 2014.
2. General Information About Non-Small Cell Lung Cancer. Bethesda, Maryland: National Cancer Institute; 2014.
3. Gupta NC, Bishop HA, Rogers JS, Tamim WZ, Reesman SD. Treatment outcome of lung cancer patients as optimized by preoperative whole-body positron emission tomography fluorodeoxyglucose imaging. Clin Lung Cancer. 2000;2: 146-150.
4. Dane B, Grechushkin V, Plank A, Moore W, Bilfinger T. PET/CT vs. non-contrast CT alone for surveillance 1-year post lobectomy for stage I non-small-cell lung cancer. Am J Nucl Med Mol Imaging. 2013;3:408-416.
5. Davison J, Mercier G, Russo G, Subramaniam RM. PET-based primary tumor volumetric parameters and survival of patients with non-small cell lung carcinoma. AJR. 2013;200:635-640.
6. Romesser PB, Qureshi MM, Shah BA, et al. Superior prognostic utility of gross and metabolic tumor volume compared to standardized uptake value using PET/ CT in head and neck squamous cell carcinoma patients treated with intensitymodulated radiotherapy. Ann Nucl Med. 2012;26:527-534.
7. Dibble EH, Karantanis D, Mercier G, Peller PJ, Kachnic LA, Subramaniam RM. PET/CT of cancer patients: part 1, pancreatic neoplasms. AJR. 2012;199:952-967.
8. Jackson T, Chung MK, Mercier G, Ozonoff A, Subramaniam RM. FDG PET/CT interobserver agreement in head and neck cancer: FDG and CT measurements of the primary tumor site. Nucl Med Commun. 2012;33:305-312.
9. Agarwal A, Chirindel A, Shah BA, Subramaniam RM. Evolving role of FDG PET/CT in multiple myeloma imaging and management. AJR. 2013;200:884-890.
10. Toba H, Sakiyama S, Otsuka H, et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography is useful in postoperative follow-up of asymptomatic non-small-cell lung cancer patients. Interact Cardiovasc Thorac Surg. 2012;15:859-864.
11. Cho S, Lee EB. A follow-up of integrated positron emission tomography/ computed tomography after curative resection of non-small-cell lung cancer in asymptomatic patients. J Thorac Cardiovasc Surg. 2010;139:1447-1451.
12. Opoka L, Szolkowska M, Podgajny Z, et al. Assessment of recurrence of nonsmall cell lung cancer after therapy using CT and integrated PET/CT. Pneumonol Alergol Pol. 2013;81:214-220.
13. Takeuchi S, Khiewvan B, Fox PS, et al. Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2014;41:906-914.
14. 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. J Nucl Med. 2004;45:1640-1646.
15. 18F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med. 2001;42:1605-1613.
16. 18F-FDG PET/CT and survival outcome in lung cancer patients. J Nucl Med. 2014;55:1062-1068.
17. Decision Memo for Positron Emission Tomography (FDG) for Solid Tumors (CAG-00181R4). CMS.gov website. http://www.cms.gov/medicare-coveragedatabase/ details/nca-decision-memo.aspx? NCAId5263. Published June 11, 2013. Accessed December 31, 2014.
18. 18F-FDG PET/CT to clinical assessment predicts overall survival in HNSCC: a retrospective analysis with follow-up for 12 years. J Nucl Med. 2013;54:2039-2045.
19. 18F-FDG PET/CT. Lung Cancer. 2013;81:71-76.